Update: Richemont Changes Vhernier Jewellery Leadership
Vhernier, the Italian jewellery maker, announces leadership changes after being acquired by Richemont, with Gianluca Brozzetti as interim CEO.
Update: Flutter Buys 56% Of NSX Group For $350M, Forming Flutter Brazil
Flutter Entertainment plc, leading online sports betting and iGaming conglomerate, announced the creation of a new business in Brazil by acquiring a 56%…
Endeavour See Strong Potential At Sabodala-Massawa Biox And Lafigué Mines
Endeavour Mining achieves commercial production at BIOX Expansion and Lafigué Growth Projects in Senegal and Côte d’Ivoire, meeting budget and schedule goals. Projects…
Salesforce Unveils Agentforce AI Agents
Salesforce introduces Agentforce, an AI suite boosting efficiency and customer satisfaction by automating tasks.
Qiagen And Bio-Manguinhos/Fiocruz Enhance Malaria, Dengue PCR Detection In Brazil
QIAGEN and Bio-Manguinhos/Fiocruz partner to improve malaria and dengue detection in Brazil's national screening efforts, deploying advanced PCR technology to detect various diseases…
Update: IHG, Hang Lung To Open Luxury Kimpton Xujiahui Shanghai By 2026
Kimpton Hotels & Restaurants partners with Hang Lung Group to open Kimpton Xujiahui Shanghai by 2026 at Grand Gateway 66 in Shanghai.
Update: Global Telecom Giants Forge New Venture to Drive Network API Adoption
Global telecom leaders, including major operators like AT&T, Verizon, and Vodafone, are teaming up with Ericsson to create a new company focused on…
Update: Kimpton Rockefeller Center In NYC With Extell In Development By Late 2025
Kimpton Hotels & Restaurants partners with Extell Development Company to open a new luxury hotel in New York City in 2025, expanding their…
Update: BP And Iberdrola To Build A 25Mw Green Hydrogen Plant In Spain, Creating 500 Jobs
bp and Iberdrola to build a 25MW green hydrogen plant in Spain, operational by 2026, creating 500 jobs and cutting 23,000 tons of…
Update: Merck’s Multiple Sclerosis Drug Mavenclad Shows Long-Term Benefits
Merck announced new data on MAVENCLAD, a treatment for multiple sclerosis, showing sustained efficacy over four years with benefits on various disease measures.…